Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7214MR)

This product GTTS-WQ7214MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7214MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6431MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ15590MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ9131MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ6496MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ2547MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ9113MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ14473MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ4904MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW